PHILADELPHIA, Pennsylvania and DUBLIN, Ireland, March 16 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY) announces that it has filed a lawsuit in the U.S. District Court of the Southern District of New York against Barr Laboratories, Inc. (Barr) for infringement of three of Shire's patents: U.S. Patent No. 5,968,976 ('976 Patent);U.S. Patent No. 7,381,428 ('428); and U.S. Patent No. 7,465,465 ('465).
The lawsuit was filed in response to an ANDA (Abbreviated New Drug Applications) filed by Barr seeking FDA approval to market and sell generic versions of Shire's 500 mg, 750 mg, and 1 g FOSRENOL(R) (Lanthanum Carbonate) products.